Bartłomiej Tomasik: Real-world Reirradiation Treatment and Disease Characteristics
Bartłomiej Tomasik, Assistant Professor at Medical University of Gdansk, posted on LinkedIn:
“Reirradiation is increasingly used in routine cancer care, but evidence to guide clinical decisions remains limited. That’s where the ReCare cohort study steps in.
Presented at ESTRO2025, this multi-centre, prospective observational study within the E²-RADiatE (EORTC–ESTRO) framework is already showing promising results:
- 243 patients with 280 lesions recruited from 14 hospitals across 10 countries.
- Most common sites: thorax (49.6%), pelvis (35%), abdomen (13.6%).
- Reirradiation completed as planned in 96.4% of cases.
- Photon therapy was the main modality (93.6%), with some particle therapy and brachytherapy.
- Systemic therapies were used in 31% of patients.
This initial analysis confirms feasibility of high-quality, prospective real-world data collection across Europe, paving the way for reliable studies on toxicity, oncologic outcomes, and quality of life.
Excitingly, the cohort will now expand to include patients undergoing reirradiation of the head and neck and CNS.
A great step forward for evidence-based reirradiation practice. Congratulations Jonas Willmann and Nicolaus Andratschke!”
More posts featuring ESTRO2025.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023